Market Conditions and Cost Pressures are Prompting Redesign of Manufacturing Facilities
This article was originally published in The Gold Sheet
The pharmaceutical and biotech manufacturing facilities of the future will be smaller and simpler than existing facilities, have more closed processes, combine clinical and commercial operations under one roof, and use more disposable equipment. Cost pressures and market conditions are behind some of these anticipated changes, some of which are occurring right now.
You may also be interested in...
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.
Criticized for giving foreign sites advance notice of inspections, agency is considering giving such notice to domestic sites too even after surprise inspections become possible.